Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FC303
- Development stage
- Unknown
- Lead developer
- FutureChem
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-FC303 is a fluorine-18 labeled small molecule radiopharmaceutical developed by FutureChem Pharma for the diagnostic imaging of prostate cancer. It functions as a high-affinity ligand for Prostate-Specific Membrane Antigen (PSMA), also known as glutamate carboxypeptidase II, which is significantly overexpressed in prostate adenocarcinoma cells and their metastases. By utilizing Positron Emission Tomography (PET), 18F-FC303 allows for the precise localization of primary tumors and metastatic spread in lymph nodes and bone tissue. Compared to first-generation Gallium-68 labeled PSMA tracers, 18F-FC303 offers potential advantages including improved image resolution due to the lower positron energy of F-18 and the ability for large-scale, centralized production and distribution. FutureChem has completed clinical trials and filed a New Drug Application (NDA) for the agent in South Korea.
- Other names
- [18F]FC30318F-labeled FC303fluorine-18 FC303fluorine18 FC303fluorine 18 FC303
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 18F-FC303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FC303.